ASX Healthcare stocks in spotlight

Mesoblast’s FDA approved Ryoncil is leading the charge in regenerative breakthroughs as it captures global attention with breakthrough cell therapies that are redefining the future of modern healthcare alongside industry leaders like Sonic Healthcare and Pro Medicus who are driving the next wave of medical innovation.

ASX Healthcare stocks

Mesoblast Limited (ASX: MSB)

Sonic Healthcare Limited (ASX: SHL) 

Pro Medicus Limited (ASX: PME)

Mesoblast Limited (ASX: MSB) 

is becoming one of the main global players in regenerative medicine with strong base in allogeneic cellular therapies for inflammatory diseases. Its FDA approved key product Ryoncil became the first mesenchymal stromal cell therapy to get approval in the U.S and its launch has already shown solid early results. In the September 2025 quarter, Ryoncil made around US$21.9 million in gross revenue, which is up by about 66% from the last quarter. This growth mainly came from wider payer coverage and more than 32 U.S. transplant centres starting to use it. Mesoblast also has a healthy balance sheet with about US$162 million in cash. Its research pipeline covers big areas like adult inflammatory bowel disease, chronic heart failure and chronic low back pain all of which are huge markets. Overall Mesoblast looks to be leading the cell based therapy space by mixing clinical progress with strong global scale up.

Sonic Healthcare Limited (ASX: SHL) 

is one of the biggest medical diagnostics company in the world, helping more than 130 million patients every year across 7 countries. In FY2025 it made around A$9.6 billion in revenue and a net profit of about A$514 million, showing a 7.6% rise from last year. It is the biggest private pathology operator in Australia, Germany, Switzerland and the U, also doing well in radiology and medical centres. The recent €423 million buy of Laboratory Group Dr. Kramer & Colleagues (LADR) in Germany makes its position even stronger. Sonic is also using digital tech to improve efficiency and accuracy. Its radiology part grew 10% on its own, and lab operations in Australia and UK went up 6% and 14% each. With a solid balance sheet and A$1.07 per share dividend, Sonic Healthcare keeps showing steady growth and strong performance in the global healthcare market.

Pro Medicus Limited (ASX: PME) 

kept breaking its own records in global medical imaging and had its best year ever in FY25. The company made revenue of around A$213 million which was 31.9% higher than last year, and net profit after tax came in at A$115.2 million which was up 39.2% with a record EBIT margin of 74%. During the year, it signed seven new enterprise imaging contracts worth A$520 million and renewed two more worth A$130 million, making its reach bigger across big U.S. hospitals and networks. In October 2025, Pro Medicus also signed a five-year deal worth A$10 million with University Hospital Heidelberg and the German Cancer Research Institute to replace old systems and grow in Europe. The company’s balance sheet looks very strong with A$210.7 million cash and no debt at all. Pro Medicus keeps leading the way in medical imaging with more speed, accuracy and innovation. 

(Source: Company Announcements)